State Key Laboratory of Complex Severe and Rare Diseases, Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Peking Union Medical College Hospital, Medical Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Sci Rep. 2024 May 2;14(1):10069. doi: 10.1038/s41598-024-59399-4.
Helicobacter pylori infection, a worldwide health issue, is typically treated with standard antibiotic therapies. However, these treatments often face resistance and non-compliance due to side effects. In this umbrella review, we aimed to comprehensively assess the impact of probiotics supplementation in different preparations on Helicobacter pylori standard treatment. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials in the Cochrane Library from inception to June 1, 2023, to identify systematic reviews with meta-analyses that focused on eradication rates, total side effects and other outcomes of interest. The most comprehensive meta-analysis was selected for data extraction. AMSTAR 2 was used to assess quality of meta-analyses. Overall, 28 unique meta-analyses based on 534 RCTs were included. The results suggests that probiotics supplementation with pooled probiotic strains was significantly associated with improved eradication rates (RR 1.10, 95% CI 1.06-1.14) and reduced risk of total side effects (RR 0.54, 95% CI 0.42-0.70) compared with standard therapy alone. Single-strained or multi-strained preparation of probiotics supplementation showed similar results. Despite Bifidobacterium spp. showing the highest potential for eradication, the study quality was critically low for most meta-analyses, necessitating further high-quality research to explore the optimal probiotic strains or their combinations for Helicobacter pylori treatment.aq_start?>Kindly check and confirm the edit made in article title.
幽门螺杆菌感染是一个全球性的健康问题,通常采用标准的抗生素疗法进行治疗。然而,由于副作用的存在,这些治疗方法常常面临耐药性和不依从性的挑战。在本次伞式评价中,我们旨在全面评估不同制剂的益生菌补充剂对幽门螺杆菌标准治疗的影响。我们检索了 PubMed、Embase 和 Cochrane 图书馆 Cochrane 对照试验中心从成立到 2023 年 6 月 1 日的系统评价,以确定专注于根除率、总副作用和其他相关结局的荟萃分析系统评价。选择最全面的荟萃分析进行数据提取。采用 AMSTAR 2 评估荟萃分析的质量。总体而言,纳入了 28 项基于 534 项 RCT 的独特荟萃分析。结果表明,与单独标准治疗相比,益生菌补充剂联合 pooled 益生菌菌株与提高的根除率(RR 1.10,95%CI 1.06-1.14)和降低的总副作用风险(RR 0.54,95%CI 0.42-0.70)显著相关。单一菌株或多菌株制备的益生菌补充剂也显示出相似的结果。尽管双歧杆菌属显示出最高的根除潜力,但大多数荟萃分析的研究质量都非常低,需要进一步的高质量研究来探索治疗幽门螺杆菌的最佳益生菌菌株或其组合。